Percentages of tetramer+ CD8 T cells in PBMCs of HHV8-seropositive patients
Clinical group, UPN . | Disease status* . | K12 . | gB . | ORF65 . | ORF6 . | ORF61 . | pp65 . |
|---|---|---|---|---|---|---|---|
| Cutoff value | 0.26 | 0.17 | 0.18 | 0.26 | 0.16 | 0.24 | |
| Group 1: transplant recipients | |||||||
| 1 | KS- | 0.2 | 0.07 | 0.23 | 0.3 | 0.16 | 2.96 |
| 2 | KS- | 0.5 | 0.01 | 0.3 | 0.42 | 1.1 | 0.43 |
| 3 | KS- | 0.12 | 0.09 | 0.32 | 0.41 | 0.08 | 0.12 |
| 4 | KS- | 0.19 | 0.08 | 0.25 | 0.29 | 0.06 | 0.29 |
| 5 | KS- | 0.31 | 0.34 | 0.38 | 1.06 | 0.37 | 12.9 |
| 6 | KS- | 0.27 | 0.17 | 0.38 | 1.4 | 0.38 | 0.06 |
| 7 | KS- | 0.52 | 0.1 | 0.63 | 0.11 | 0.30 | 0.53 |
| 8 | KS- | 0.26 | 0.22 | 0.17 | 0.65 | 0.2 | 0.38 |
| 9 | KSR | 0.59 | 0.3 | 0.28 | 0.03 | 0.70 | 1.72 |
| 10 | KSR | 0.31 | 0.22 | 0.30 | 0.48 | 0.12 | 0.24 |
| 11 | KS+ | 1.98 | 2.06 | 2.2 | 1.85 | 0.45 | — |
| 12 | KS+ | 0.22 | 0.09 | 0.01 | 0.23 | 0.12 | 0.15 |
| Group 2: HIV | |||||||
| 13 | KS+ | 0.18 | 0.24 | 0.23 | 0.11 | 0.05 | 0.02 |
| 14 | KS+ | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 4.2 |
| 15 | KS+ | 0.13 | 0.18 | 0.13 | 0.24 | 0.21 | 3.2 |
| 16 | KS+ | 0.38 | 0.19 | 0.33 | 0.56 | 0.08 | — |
| 17 | KS+ | 0.04 | 0.00 | 0.02 | 0.13 | 0.04 | 2.75 |
| 18 | KS+ | 0.31 | 0.14 | 0.26 | 0.34 | 0.13 | — |
| 19 | KS+ | 0.28 | 0.2 | 0.39 | 0.46 | 0.11 | — |
| 20 | KSR | 0.08 | 0.01 | 0.01 | 0.02 | 0.07 | 5.65 |
| 21 | KSR | 0.03 | 0.00 | 0.01 | 0.11 | 0.15 | 5.33 |
| 22 | KSR | 0.04 | 0.02 | 0.02 | 0.09 | 0.15 | 3.66 |
| 23 | KSR | 0.09 | 0.03 | 0.01 | 0.06 | 0.03 | 1.00 |
| 24 | KSR | 0.04 | 0.01 | 0.02 | 0.1 | 0.03 | 0.7 |
| 25 | KSR | 0.25 | 0.06 | 0.19 | 0.05 | 0.09 | 6.98 |
| 26 | KSR | 0.01 | 0.00 | 0.01 | 0.13 | 0.24 | 0.95 |
| 27 | KSR | 0.22 | 0.04 | 0.13 | 0.04 | 0.05 | 0.16 |
| 28 | KSR | 0.1 | 0.08 | 0.07 | 0.2 | 0.1 | 4.38 |
| 29 | KSR | 0.11 | 0.03 | 0.06 | 0.06 | 0.02 | 1.3 |
| 30 | KSR | 0.2 | 0.02 | 0.1 | — | — | 1.23 |
| 31 | KSR | 0.1 | 0.1 | 0.13 | 0.04 | 0.03 | 0.09 |
| 32 | KSR | 0.25 | 0.07 | 0.1 | 0.05 | 0.12 | 0.5 |
| 33 | KSR | 0.37 | 0.07 | 0.1 | 0.03 | 0.05 | 0.02 |
| 34 | KSR | 0.25 | 0.04 | 0.07 | 0.04 | 0.04 | 2.66 |
| 35 | KSR | 0.21 | 0.1 | 0.24 | 0.33 | 0.1 | 0.54 |
| 36 | KSR | 0.2 | 0.16 | 0.2 | 0.26 | 0.17 | 6.00 |
| Group 3: classical | |||||||
| 37 | KS+ | 0.15 | 0.09 | 0.28 | 0.18 | 0.13 | 2.00 |
| 38 | KS+ | 0.17 | 0.07 | 0.15 | 0.45 | 0.11 | 0.06 |
| 39 | KS+ | 0.15 | 0.15 | 0.06 | 0.13 | 0.06 | — |
| 40 | KS+ | 0.2 | 0.14 | 0.21 | 0.28 | 0.38 | 1.29 |
| 41 | KS+ | 0.13 | 0.3 | 0.17 | 0.22 | 0.31 | 4.64 |
| 42 | KS+ | 0.52 | 0.62 | 0.57 | 0.49 | 0.39 | 0.31 |
| 43 | KS+ | 0.07 | 0.21 | 0.2 | 0.53 | 0.03 | 0.11 |
| 44 | KS+ | 0.35 | 0.2 | 0.65 | 0.35 | 0.32 | 2.85 |
| 45 | KS+ | 0.11 | 0.4 | 0.1 | 0.07 | 0.08 | 1.48 |
| 46 | KSR | 0.1 | 0.08 | 0.11 | 0.17 | 0.12 | 0.07 |
| 47 | KSR | 0.12 | 0.57 | 0.32 | — | — | — |
| 48 | KSR | 0.31 | 0.45 | 0.4 | 0.93 | 0.2 | 2.39 |
| Total patients with positive response, % | 31 | 35 | 50 | 43.5 | 32 | 74 | |
| Mean percentage of tetramer+ cells | 0.37 | 0.31 | 0.3 | 0.44 | 0.31 | 2.96 |
Clinical group, UPN . | Disease status* . | K12 . | gB . | ORF65 . | ORF6 . | ORF61 . | pp65 . |
|---|---|---|---|---|---|---|---|
| Cutoff value | 0.26 | 0.17 | 0.18 | 0.26 | 0.16 | 0.24 | |
| Group 1: transplant recipients | |||||||
| 1 | KS- | 0.2 | 0.07 | 0.23 | 0.3 | 0.16 | 2.96 |
| 2 | KS- | 0.5 | 0.01 | 0.3 | 0.42 | 1.1 | 0.43 |
| 3 | KS- | 0.12 | 0.09 | 0.32 | 0.41 | 0.08 | 0.12 |
| 4 | KS- | 0.19 | 0.08 | 0.25 | 0.29 | 0.06 | 0.29 |
| 5 | KS- | 0.31 | 0.34 | 0.38 | 1.06 | 0.37 | 12.9 |
| 6 | KS- | 0.27 | 0.17 | 0.38 | 1.4 | 0.38 | 0.06 |
| 7 | KS- | 0.52 | 0.1 | 0.63 | 0.11 | 0.30 | 0.53 |
| 8 | KS- | 0.26 | 0.22 | 0.17 | 0.65 | 0.2 | 0.38 |
| 9 | KSR | 0.59 | 0.3 | 0.28 | 0.03 | 0.70 | 1.72 |
| 10 | KSR | 0.31 | 0.22 | 0.30 | 0.48 | 0.12 | 0.24 |
| 11 | KS+ | 1.98 | 2.06 | 2.2 | 1.85 | 0.45 | — |
| 12 | KS+ | 0.22 | 0.09 | 0.01 | 0.23 | 0.12 | 0.15 |
| Group 2: HIV | |||||||
| 13 | KS+ | 0.18 | 0.24 | 0.23 | 0.11 | 0.05 | 0.02 |
| 14 | KS+ | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 4.2 |
| 15 | KS+ | 0.13 | 0.18 | 0.13 | 0.24 | 0.21 | 3.2 |
| 16 | KS+ | 0.38 | 0.19 | 0.33 | 0.56 | 0.08 | — |
| 17 | KS+ | 0.04 | 0.00 | 0.02 | 0.13 | 0.04 | 2.75 |
| 18 | KS+ | 0.31 | 0.14 | 0.26 | 0.34 | 0.13 | — |
| 19 | KS+ | 0.28 | 0.2 | 0.39 | 0.46 | 0.11 | — |
| 20 | KSR | 0.08 | 0.01 | 0.01 | 0.02 | 0.07 | 5.65 |
| 21 | KSR | 0.03 | 0.00 | 0.01 | 0.11 | 0.15 | 5.33 |
| 22 | KSR | 0.04 | 0.02 | 0.02 | 0.09 | 0.15 | 3.66 |
| 23 | KSR | 0.09 | 0.03 | 0.01 | 0.06 | 0.03 | 1.00 |
| 24 | KSR | 0.04 | 0.01 | 0.02 | 0.1 | 0.03 | 0.7 |
| 25 | KSR | 0.25 | 0.06 | 0.19 | 0.05 | 0.09 | 6.98 |
| 26 | KSR | 0.01 | 0.00 | 0.01 | 0.13 | 0.24 | 0.95 |
| 27 | KSR | 0.22 | 0.04 | 0.13 | 0.04 | 0.05 | 0.16 |
| 28 | KSR | 0.1 | 0.08 | 0.07 | 0.2 | 0.1 | 4.38 |
| 29 | KSR | 0.11 | 0.03 | 0.06 | 0.06 | 0.02 | 1.3 |
| 30 | KSR | 0.2 | 0.02 | 0.1 | — | — | 1.23 |
| 31 | KSR | 0.1 | 0.1 | 0.13 | 0.04 | 0.03 | 0.09 |
| 32 | KSR | 0.25 | 0.07 | 0.1 | 0.05 | 0.12 | 0.5 |
| 33 | KSR | 0.37 | 0.07 | 0.1 | 0.03 | 0.05 | 0.02 |
| 34 | KSR | 0.25 | 0.04 | 0.07 | 0.04 | 0.04 | 2.66 |
| 35 | KSR | 0.21 | 0.1 | 0.24 | 0.33 | 0.1 | 0.54 |
| 36 | KSR | 0.2 | 0.16 | 0.2 | 0.26 | 0.17 | 6.00 |
| Group 3: classical | |||||||
| 37 | KS+ | 0.15 | 0.09 | 0.28 | 0.18 | 0.13 | 2.00 |
| 38 | KS+ | 0.17 | 0.07 | 0.15 | 0.45 | 0.11 | 0.06 |
| 39 | KS+ | 0.15 | 0.15 | 0.06 | 0.13 | 0.06 | — |
| 40 | KS+ | 0.2 | 0.14 | 0.21 | 0.28 | 0.38 | 1.29 |
| 41 | KS+ | 0.13 | 0.3 | 0.17 | 0.22 | 0.31 | 4.64 |
| 42 | KS+ | 0.52 | 0.62 | 0.57 | 0.49 | 0.39 | 0.31 |
| 43 | KS+ | 0.07 | 0.21 | 0.2 | 0.53 | 0.03 | 0.11 |
| 44 | KS+ | 0.35 | 0.2 | 0.65 | 0.35 | 0.32 | 2.85 |
| 45 | KS+ | 0.11 | 0.4 | 0.1 | 0.07 | 0.08 | 1.48 |
| 46 | KSR | 0.1 | 0.08 | 0.11 | 0.17 | 0.12 | 0.07 |
| 47 | KSR | 0.12 | 0.57 | 0.32 | — | — | — |
| 48 | KSR | 0.31 | 0.45 | 0.4 | 0.93 | 0.2 | 2.39 |
| Total patients with positive response, % | 31 | 35 | 50 | 43.5 | 32 | 74 | |
| Mean percentage of tetramer+ cells | 0.37 | 0.31 | 0.3 | 0.44 | 0.31 | 2.96 |
Cutoff value was defined for each tetramer as the mean frequency + 2 SD of tetramer+ cells in 18 HLA-A2- HHV8+ individuals. Responses in patients were considered positive if the percentage of tetramer+ cells was above the cutoff value. Positive values are shown in italics.
UPN indicates unique patient number; and —, not done.
Disease status at time of analysis, defined as patients with ongoing KS (KS+), patients with KS in remission (KSR), and patients without KS lesions (KS-).